References
US Renal Data System. USRDS 1998 Annual Data Report. National Institute of Diabetes and Digestive and Kidney Disease: Bethesda, MD, USA, 1998.
Parving HH, Andersen AR, Smidt UM, Svendsen PA . Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1: 1175–1179.
Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878.
Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
Buchanan TA et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 1995; 96: 354–360.
Kaufman LN, Peterson MM, DeGrange LM . Pioglitazone attenuates diet-induced hypertension in rats. Metabolism 1995; 44: 1105–1109.
Fujii M et al. Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism 1997; 46: 981–983.
Buckingham RE et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998; 47: 1326–1334.
Bakris G et al. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. J Hum Hypertens 2003; 17: 7–12.
Ogihara T et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8: 316–320.
Sung BH, Izzo, Jr JL, Dandona P, Wilson MF . Vaso-dilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999; 34: 83–88.
Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1988; 351: 1755–1762.
Grossman E . Does the ‘J-curve’ still hold in the post ‘HOT’ era?. J Hum Hypertens 1998; 12: 729–730.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grossman, E. Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al. J Hum Hypertens 17, 5–6 (2003). https://doi.org/10.1038/sj.jhh.1001474
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001474
- Springer Nature Limited